Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
Overview
US consumer healthcare firm's fiscal Q1 revenue rose 6.5%, beating analyst expectations
Adjusted diluted EPS for fiscal Q1 rose to $0.98 from $0.95 last year
Company closed Breathe Right and LaCorium acquisitions, raising fiscal 2027 outlook
Outlook
Company raises fiscal 2027 revenue outlook to $1.29 bln-$1.315 bln including acquisitions
Prestige Consumer Healthcare expects fiscal 2027 adjusted diluted EPS of $4.55-$4.65
Company projects fiscal 2027 adjusted free cash flow of $270 mln or more
Result Drivers
CATEGORY STRENGTH - Organic growth in Gastrointestinal and Dermatological categories contributed to Q1 revenue gains
ACQUISITION IMPACT - Breathe Right acquisition added $6 mln to Q1 revenue
WORKING CAPITAL - Higher adjusted free cash flow was due to the timing of working capital
Company press release: ID:nGNX18QPtM
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $265.71 mln | $250.33 mln (7 Analysts) |
Q1 Net Income |
| $29.18 mln |
|
Q1 Gross Profit |
| $136.19 mln |
|
Q1 Operating Expenses |
| $83.67 mln |
|
Q1 Operating Income |
| $52.52 mln |
|
Q1 Pretax Profit |
| $38.54 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $69.50, about 31.2% above its August 5 closing price of $52.98
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago
Reuters Recommended Reads
Aug 5 - Edgewell Personal Care Q3 sales miss estimates; narrows FY outlook
Aug 5 - Ireland's Perrigo Q2 profit beats on portfolio streamlining
Aug 4 - P&G buys supplements maker Thorne for $3.8 billion as wellness push intensifies
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Prestige Consumer Healthcare
See all newsPrestige Consumer Healthcare Inc. reports results for the quarter ended September 30 - Earnings Summary
Prestige Consumer Healthcare Q2 revenue beats on acquisition boost
Prestige Consumer Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
Brief: Prestige Consumer Healthcare Inc. Announces Offering Of $400 Million Senior Notes